Aimmune Therapeutics to Host Analyst and Investor Event Following Oral Late-Breaking Presentation of Phase 3 PALISADE Results on Sunday, March 4, at the AAAAI-WAO Joint Congress in Orlando
Aimmune Therapeutics’ Pivotal Phase 3 PALISADE Trial of AR101 Meets Primary Endpoint in Patients With Peanut Allergy
Aimmune Therapeutics Expands Scientific Advisory Board With Appointments of George du Toit, M.B., B.Ch., and Wayne Shreffler, M.D., Ph.D.
Aimmune Therapeutics Broadens and Extends Supply Agreement With Golden Peanut and Tree Nuts for AR101 for Peanut Allergy
Jotin Marango M.D., Ph.D.
Roth Capital Partners, LLC